ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

itepekimab

Also written as “Itepekimab (SAR440340)”, “REGN3500” and “Itepekimab SAR440340”.

Its studies are mostly in Nasal Polyps · Pulmonary Disease, Chronic Obstructive · Asthma · Dermatitis, Atopic · Bronchiectasis, led by 2 companies.

Drug pageItepekimab: every studyAll 17 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Dec 30, 202017 company-led studies, 3 open or runningNext primary completion: Feb 17, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Sanofi123 open or runningphase 3since Dec 30, 2020Dec 15, 2017Feb 17, 2027phase 3 · NCT07424144
Regeneron Pharmaceuticalsits history only50 open or runningphase 2since Nov 7, 2018Oct 25, 2016none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Sanofi only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Dec 15, 2017First study: phase 2 study in AsthmaFirst studyNCT03387852 · 296 enrolled · United States, Argentina, Chile and more
  2. May 17, 2018Phase 2 study in Pulmonary Disease, Chronic ObstructiveNCT03546907 · 343 enrolled · United States, Argentina, Australia and more
  3. Dec 9, 2019Named itepekimabINNProposed as its International Nonproprietary Name in WHO's List 122 · before, REGN3500, SAR440340
  4. Dec 30, 2020Phase 3 study in Pulmonary Disease, Chronic ObstructiveNCT04701983 · 1,127 enrolled · United States, Argentina, Bulgaria and more
  5. Feb 8, 2021Phase 3 study in Pulmonary Disease, Chronic ObstructiveNCT04751487 · 1,234 enrolled · United States, Argentina, Brazil and more
  6. Apr 6, 2022Phase 2 study in Pulmonary Disease, Chronic ObstructiveNCT05326412 · 49 enrolled · United States, Belgium, Brazil and more
  7. Jan 5, 2024Phase 3 study in Pulmonary Disease, Chronic ObstructiveNCT06208306 · 669 enrolled · United States, Argentina, Brazil and more
  8. Feb 20, 2024Phase 2 study in BronchiectasisNCT06280391 · 314 enrolled · United States, Argentina, Brazil and more
  9. Nov 12, 2024Phase 2 study in Chronic Rhinosinusitis Without Nasal PolypsNCT06691113 · 66 enrolled · United States, Argentina, Belgium and more
  10. Feb 14, 20252 phase 3 studies in Chronic Rhinosinusitis With Nasal PolypsNCT06834360, NCT06834347
  11. Feb 13, 2026Phase 3 study in Chronic Rhinosinusitis With Nasal PolypsNCT07424144 · 59 enrolled · United States, Argentina, Australia and more
  12. Mar 16, 2026Phase 3 study in Chronic Rhinosinusitis With Nasal PolypsNCT07484230

Ahead

  1. Feb 17, 2027Primary completion: phase 3 study in Chronic Rhinosinusitis With Nasal PolypsNCT07424144

TargetBeta

IL33 →read by rule
“Interleukin-33 inhibitor”ChEMBL 37, by rule

Other programs on IL33

ProgramCompanyFurthest phaseStudies
GSK3862995BGlaxoSmithKlinephase 25
ompekimigPfizerphase 23
HXN-1013ruleHelixon Biotechnology (Suzhou)phase 11
HY6725ruleNewsoara Biopharmaphase 11

Studies

All 12 Sanofi leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07484230Chronic Rhinosinusitis With Nasal Polyps3WithdrawnOct 20, 20270
NCT07424144Chronic Rhinosinusitis With Nasal Polyps · United States, Argentina, Australia and more3Active, not recruitingFeb 17, 202759
NCT06834360Chronic Rhinosinusitis With Nasal Polyps · United States, Argentina, Australia and more3Active, not recruitingSep 24, 2026216
NCT06834347Chronic Rhinosinusitis With Nasal Polyps · United States, Argentina, Austria and more3Active, not recruitingSep 23, 2026231
NCT06691113Chronic Rhinosinusitis Without Nasal Polyps · United States, Argentina, Belgium and more2CompletedMar 31, 202666
NCT06280391Bronchiectasis · United States, Argentina, Brazil and more2CompletedSep 16, 2025314
NCT06208306Pulmonary Disease, Chronic Obstructive · United States, Argentina, Brazil and more3CompletedSep 10, 2026669
NCT05326412Pulmonary Disease, Chronic Obstructive · United States, Belgium, Brazil and more2CompletedMar 5, 202549
NCT04751487Pulmonary Disease, Chronic Obstructive · United States, Argentina, Brazil and more3CompletedApr 21, 20251,234
NCT04701983Pulmonary Disease, Chronic Obstructive · United States, Argentina, Bulgaria and more3CompletedApr 11, 20251,127
NCT03546907Pulmonary Disease, Chronic Obstructive · United States, Argentina, Australia and more2CompletedOct 3, 2019343
NCT03387852Asthma · United States, Argentina, Chile and more2CompletedMar 21, 2019296

How it is read

Names in the registry

  • “Itepekimab (SAR440340)”, 7 entries
  • “REGN3500”, 5 entries
  • “Itepekimab SAR440340”, 3 entries
  • “SAR440340”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.